Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2004-10-15
2011-12-13
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C536S023530, C435S006120, C435S007100, C435S069600, C435S320100, C424S133100
Reexamination Certificate
active
08076459
ABSTRACT:
The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an IG-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct is provided. Further aspects of the invention are vectors and host cells comprising the nucleic acid sequences, a process for the production of the construct and composition comprising the construct. The invention also provides the use of the constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
REFERENCES:
patent: 4361549 (1982-11-01), Kung et al.
patent: 5929212 (1999-07-01), Jolliffe et al.
patent: 6491916 (2002-12-01), Bluestone et al.
patent: 7235641 (2007-06-01), Kufer et al.
patent: 7635472 (2009-12-01), Kufer et al.
patent: 2002/0009430 (2002-01-01), Lindhofer et al.
patent: 2004/0162411 (2004-08-01), Lanzavecchia
patent: 0 620 276 (1994-10-01), None
patent: 0620276 (1994-10-01), None
patent: WO 92/10755 (1992-06-01), None
patent: WO 92 15683 (1992-09-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 99/54440 (1999-10-01), None
patent: WO 99/54440 (1999-10-01), None
patent: WO 00/34317 (2000-06-01), None
patent: WO 02/012899 (2002-02-01), None
patent: WO 02/066514 (2002-08-01), None
patent: WO 02/066514 (2002-08-01), None
patent: WO 02/069232 (2002-09-01), None
patent: WO 0269232 (2002-09-01), None
patent: WO 02/079415 (2002-10-01), None
Paul. Fundamental Immunology, 3rd Edition, 1993. pp. 292-295.
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Colman. Effects of amino acid sequence changes on antibody-antigen interactions. Research in Immunology, 1994. vol. 145, pp. 33-36.
Mac Callum, Martin and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanzied monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Granziero, Krajewski, Farness, Yuan, Courtney, Jackson, Peterson, and Vitiello. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. European Journal of Immunology, 1999. vol. 29, pp. 1127-1138.
Byers. What can randomized controlled trials tell us about nutrition and cancer prevention? CA Cancer Journal, 1999. vol. 49, pp. 353-361.
Skolnick and Fetrow. From genes to protein structure and function: novel application of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin binding and mitogenic activities of heparin binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Eck and Wilson. “Gene-based Therapy” Goodman & Gilman's The Pharmacological basis of Therapeutics, McGraw-Hill, New York, NY. 1996. pp. 77-101.
Verma and Somia. Gene therapy- promises, problems, and prospects. Nature, 1997. vol. 389, pp. 239-242.
Pfeifer and Verma. Gene therapy: promises and problems. Annual Review of Genomics and Human Genetics, 2001. vol. 2, pp. 177-211.
Vile, Russell, and Lemoine. Cancer gene therapy: hard lessons and new courses. Gene Therapy, 2000, vol. 7 pp. 2-8.
Kelland, et al. “Of mice and men”: values and liabilities of the athymic nude mouse model in anticancer drug development. European Journal of Cancer, 2004. vol. 40, pp. 827-836.
K. Maletz, et al., “Bispecific Single-Chain Antibodies As Effective Tools For Eliminating Epithelial Cancer Cells From Human Stem Cell Preparations by Redirected Cell Cytotoxicity,” Int. J. Cancer, vol. 93, pp. 409-416 (2001).
The Notice of Reasons for Rejection received in the corresponding Japanese Patent Application No. 2006-534709, dated Jun. 7, 2010. (with translation).
Foote, et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”,J. Mol. Biol., 2002, vol. 224, pp. 487-499.
Maletz, et al., “Bispecific Single-Chain Antibodies as Effective Tools for Eliminating Epithelial Cancer Cells from Human Stem Cell Preparations by Redirected Cell Cytotoxicity”,Int. J. Cancer, 2001, vol. 93, pp. 409-416.
Winter, et al., “Humanized antibodies”,Immunology Today, 1993, vol. 14, No. 6, pp. 243-246.
Maletz, et. al., “Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity”,International Journal of Cancer, vol. 93, No. 3, Aug. 2001, pp. 409-416.
The European Search Report received in the related European Patent Application 10177720.9, dated Feb. 11, 2011.
Bäuerle Patrick
Carr Francis J.
Hamilton Anita A.
Hofmeister Robert
Itin Christian
Foley & Lardner LLP
Gussow Anne M.
Micromet AG
LandOfFree
Multispecfic deimmunized CD3-binders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multispecfic deimmunized CD3-binders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multispecfic deimmunized CD3-binders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4266485